Literature DB >> 16574281

Estimating the risk population in relation to influenza vaccination policy.

Douglas M Fleming1, Alex J Elliot.   

Abstract

There are many small differences in national influenza vaccination polices, some are age related and others morbidity related. This study examines a large English general practice database for 2003 to estimate the size of the England and Wales population at risk because of co-morbidity and to make recommendations on the choice of morbidity codes for use when estimating demand for vaccine and in auditing medical records to assess vaccination uptake. Morbidity codes relevant to the assessment of risk were defined and the database was analysed to estimate the annual period prevalence of the various diseases and groups of diseases. A set of morbidity codes is recommended which taken together include 3.2% of age group 0-14 years, 7.5% of 15-44 years and 16.6% of 45-64 years.

Mesh:

Substances:

Year:  2006        PMID: 16574281     DOI: 10.1016/j.vaccine.2006.02.053

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

Review 1.  Influenza vaccination in the elderly.

Authors:  Jan Smetana; Roman Chlibek; Jana Shaw; Miroslav Splino; Roman Prymula
Journal:  Hum Vaccin Immunother       Date:  2017-08-04       Impact factor: 3.452

2.  Pneumococcal vaccination rates in adults in Germany: an analysis of statutory health insurance data on more than 850,000 individuals.

Authors:  Ulrike Theidel; Alexander Kuhlmann; Anja Braem
Journal:  Dtsch Arztebl Int       Date:  2013-11-01       Impact factor: 5.594

3.  Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.

Authors:  Pawel Grzesiowski; Raquel Aguiar-Ibáñez; Aleksandra Kobryń; Laure Durand; Pierre-Emmanuel Puig
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

4.  Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany.

Authors:  Alexander Kuhlmann; Ulrike Theidel; Mathias W Pletz; J-Matthias Graf von der Schulenburg
Journal:  Health Econ Rev       Date:  2012-03-30

5.  Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.

Authors:  Oliver Damm; Martin Eichner; Markus Andreas Rose; Markus Knuf; Peter Wutzler; Johannes Günter Liese; Hagen Krüger; Wolfgang Greiner
Journal:  Eur J Health Econ       Date:  2014-05-25

6.  The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study.

Authors:  Markus A Rose; Oliver Damm; Wolfgang Greiner; Markus Knuf; Peter Wutzler; Johannes G Liese; Hagen Krüger; Ulrich Wahn; Tom Schaberg; Markus Schwehm; Thomas F Kochmann; Martin Eichner
Journal:  BMC Infect Dis       Date:  2014-01-22       Impact factor: 3.090

7.  The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model.

Authors:  Laure-Anne Van Bellinghen; Genevieve Meier; Ilse Van Vlaenderen
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

8.  Influenza risk groups in Norway by education and employment status.

Authors:  Birgitte Klüwer; Kjersti Margrethe Rydland; Ida Laake; Megan Todd; Lene Kristine Juvet; Svenn-Erik Mamelund
Journal:  Scand J Public Health       Date:  2021-12-20       Impact factor: 3.199

9.  Immunogenicity of a trivalent influenza vaccine and persistence of induced immunity in adults aged ≥60 years in Taizhou City, Zhejiang Province, China, during the 2018-2019 season.

Authors:  Yuting Liao; Yan Jin; Hangjie Zhang; Juan Yang; Jian Fu; Huakun Lv
Journal:  Hum Vaccin Immunother       Date:  2022-06-10       Impact factor: 4.526

10.  Threat-responsiveness and the decision to obtain free influenza vaccinations among the older adults in Taiwan.

Authors:  Ying-Chun Li; Chi-Mei Liu
Journal:  BMC Public Health       Date:  2009-07-31       Impact factor: 3.295

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.